Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies

Fig. 3

Mean Change From Baseline in ASDAS Scores, and Proportion of Patients Achieving ASDAS Inactive Disease (ID) and ASDAS Low Disease Activity (LDA), at Weeks 12 and 24 From SELECT-PsA 1 (non-bDMARD-IR) and SELECT-PsA 2 (bDMARD-IR). Mean change from baseline in ASDAS (CRP) scores at weeks 12 and 24 for PsA patients with axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria treated with placebo, upadacitinib 15 mg QD, or adalimumab 40 mg EOW from SELECT-PsA 1 (A) or with placebo or upadacitinib 15 mg QD from SELECT-PsA 2 (B). Proportions of PsA patients with axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria treated with placebo, upadacitinib 15 mg QD, or adalimumab 40 mg EOW that achieved ASDAS ID (C) or ASDAS LDA (E) at weeks 12 and 24 from SELECT-PsA 1. Proportions of PsA patients with axial involvement defined by either criterion treated with placebo or upadacitinib 15 mg QD that achieved ASDAS ID (D) or ASDAS LDA (F) at weeks 12 and 24 from SELECT-PsA 2. ASDAS ID defined as score < 1.3; LDA defined as score < 2.1. ASDAS was analyzed using mixed-effect model for repeated measures and are shown as least squares means with 95% CIs. ASDAS ID and ASDAS LDA were analyzed using Cochran-Mantel–Haenszel tests with non-responder imputation and are shown as response rates with 95% CIs. ****P < 0.0001, ***P < 0.001, **P < 0.01, upadacitinib 15 mg versus placebo; ##P < 0.01, upadacitinib 15 mg versus adalimumab; nominal P values are shown and were not multiplicity controlled. ADA, adalimumab; ASDAS, Ankylosing Spondylitis Disease Activity Score; bDMARD, biologic disease-modifying antirheumatic drug; CI, confidence interval; EOW, every other week; ID, inactive disease; IR, inadequate response; LDA, low disease activity; PBO, placebo; PRO, patient-reported outcome; PsA, psoriatic arthritis; QD, once daily; UPA, upadacitinib

Back to article page